June 16, 2004Blood Coagulation & Fibrinolysis
807 C/T Polymorphism of the glycoprotein Ia gene and pharmacogenetic modulation of platelet response to dual antiplatelet treatment
Why the study?
Does the 807 C/T polymorphism of the GP Ia gene modulate platelet response to clopidogrel in patients undergoing coronary stenting?
Population
44 patients undergoing coronary stenting receiving a 300 mg clopidogrel loading dose
Comparison
T-allele carriers of the 807 C/T polymorphism of… vs Non-carriers of the T allele
Design
Cohort
Follow-up
24 hours
Authors
Discussion
Loading...
Member takes
Implication
T allele may attenuate clopidogrel response post-stenting; hypothesis-generating for GP Ia genotyping before routine clinical use.
Structured PICO
Does the 807 C/T polymorphism of the GP Ia gene modulate platelet response to clopidogrel in patients undergoing coronary stenting?
P
Population
44 patients undergoing coronary stenting receiving a 300 mg clopidogrel loading dose
I
Intervention
T-allele carriers of the 807 C/T polymorphism of the glycoprotein (GP) Ia gene (ITGA2)
C
Comparator
Non-carriers of the T allele
O
Outcome
Platelet aggregation assessed by light transmittance aggregometry following adenosine diphosphate and collagen stimuli at baseline, and 10 min, 4 h and 24 h after clopidogrel front loadingsurrogate
The T allele of the GP Ia gene attenuates clopidogrel's antiplatelet effects against collagen-induced aggregation, suggesting a potential mechanism for increased thrombotic risk in carriers undergoing coronary stenting.
Cite This Study
Angiolillo et al. (2004) studied this question.